Mindray Medical downgraded to Neutral from Buy at BofA/Merrill BofA/Merrill downgraded Mindray Medical due to weakness in emerging market sales following the Q1 report.
Mindray Medical still sees FY13 adjusted net income up 15% over prior year Company still sees FY13 revenue up at least 17% over prior year. This guidance excludes the tax benefits of $19.4M related to the National Key Software Enterprise, which was recognized in Q1, and assumes a corporate income tax rate of 15% applicable to the Shenzhen subsidiary.
Subscribe for More Information